Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

Journal of Clinical Oncology

Volumn 18, Issue 4, 2000, Pages 708-715

  Fine, Howard A ^a   Figg, William D ^a   Jaeckle, Kurt ^a   Wen, Patrick Y ^a   Kyritsis, Athanassios P ^a   Loeffler, Jay S ^a   Levin, Victor A ^a   Black, Peter M ^a   Kaplan, Richard ^a   Pluda, James M ^a   Yung, W K Alfred ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CLINICAL TRIAL; CONSTIPATION; DEMOGRAPHY; DISEASE MARKER; DRUG TOLERABILITY; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; MALE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEDATION;

EID: 0033954292     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.4.708     Document Type: Article

References (34)

1. DeAngelis LM, Yahalom J, Thaler HT, et al: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635-643, 1992
2. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360-364, 1988
3. Fine HA, Mayer RJ: Primary central nervous system lymphoma. Ann Int Med 119:1093-1104, 1993
4. Fine HA: The basis for current treatment recommendations for malignant gliomas. J Neurooncol 20:111-121, 1994
5. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
6. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
7. Toi M, Inada K, Suzuki H, et al: Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with VEGF expression. Breast Cancer Res Treat 36:193-204, 1995
8. Plate KH, Breier G, Weich HA, et al: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848, 1992
9. Shweiki D, Itin A, Soffer D, et al: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845, 1992
10. Brem S, Cotran R, Folkman J: Tumor angiogenesis: A quantitative method for histologic grading. J Natl Cancer Inst 48:347-356, 1972
11. Takahashi J, Fukumoto M, Igorshi K, et al: Correlations of bFGF expression levels with degree of malignancy and vascularity in human gliomas. J Neurosurg 76:792-798, 1992
12. Zagzag D, Miller D, Sato Y, et al: Immunohistochemical localization of bFGF in astrocytomas. Cancer Res 50:7393-7398, 1990
13. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
14. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
15. Levin VA, Wilson CV, Crafts D, et al: Criteria for evaluating patients undergoing chemotherapy for malignant brain tumor. J Neurosurg 47:329-335, 1977
16. Millauer B, Shawver LK, Plate KH, et al: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994
17. Maxwell M, Naber SP, Wolfe HJ, et al: Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86:131-140, 1990
18. Hsu SC, Volpert OV, Steck PA, et al: Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin. Cancer Res 56:5684-5691, 1996
19. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenesis switch during tumorigenesis. Cell 86: 353-364, 1996
20. Fotsis T, Zhang Y, Pepper MS, et al: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368:237-239, 1994
21. Ingber D, Fujita T, Kishimoto S, et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555-557, 1990
22. Lee JK, Choi B, Sobel RA, et al: Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg 73:429-435, 1990
23. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
24. Sakamoto N, Iwahana M, Tanaka NG, et al: Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDP-GYIGSR-NH2. Cancer Res 51:903-906, 1991
25. Tanaka T, Manome Y, Wen P, et al: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 3:1-6, 1997
26. Tanaka T, Cao Y, Folkman J, et al: Viral-vector mediated antiangiogenic gene therapy utilizing an angiostatin cDNA. Cancer Res 58:3362-3369, 1998
27. Rovelli A, Arrigo C, Nesi F, et al: The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 21:577-581, 1998
28. Hamuryudan V, Mat C, Saip S, et al: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443-450, 1998
29. Moller DR, Wysocka M, Greenlee BM, et al: Inhibition of IL-12 production by thalidomide. J Immunol 159:5157-5161, 1997
30. Jacobson JM, Greenspan JS, Spritzer J, et al: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 336:1487-1493, 1997
31. Kenyon BM, Browne F, D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971-978, 1997
32. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704, 1992
33. Teicher BA, Holder SA, Ara G, et al: Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 38:169-177, 1996
34. Teicher BA, Holden SA, Ara G, et al: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Cancer 57:1-6, 1994